Skip to content
Oncology Research Hub

San Francisco, California

Cancer clinical trials in San Francisco, CA

214 cancer studies are recruiting participants at sites in San Francisco as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

San Francisco at a glance

  • 214 studies are recruiting at a site in San Francisco.
  • By phase: Early Phase 1 (4), Phase 1 (33), Phase 1/2 (28), Phase 2 (46), Phase 2/3 (5), Phase 3 (58), No phase (14), Observational (26). Studies of devices and behavioral approaches have no phase.
  • By sponsor: university, hospital or other (102), industry (98), government (14).
  • By research area: Breast Cancer (58), Prostate Cancer (45), Lung Cancer (41), Lymphoma (40), Melanoma (15), Pancreatic Cancer (15).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in San Francisco

Basic details from each study's public record (the 30 most recently updated of 214). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    California Pacific Medical Center-Pacific Campus
    Registry record
    NCT06058377 · updated
  2. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    UCSF Helen Diller Family Comprehensive Cancer Center
    Registry record
    NCT06638307 · updated
  3. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016)
    Registry record
    NCT06841354 · updated
  4. Mirai-MRI: Validation of AI Models for Breast Cancer Risk

    • No phase
    • Ages 40 to 89
    • Female participants
    Sponsor
    University of California, San Francisco
    Study site
    University of California, San Francisco
    Registry record
    NCT07121972 · updated
  5. Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    University of California, San Francisco
    Study site
    University of California, San Francisco
    Registry record
    NCT05964504 · updated
  6. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    California Pacific Medical Center-Pacific Campus
    Registry record
    NCT07391774 · updated
  7. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    ORIC Pharmaceuticals
    Study site
    University of California, San Francisco
    Registry record
    NCT05315700 · updated
  8. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Kaiser Permanente - San Francisco ( Site 0080)
    Registry record
    NCT06393374 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.

Lung cancer studies recruiting in San Francisco

  1. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    California Pacific Medical Center-Pacific Campus · Kaiser Permanente-San Francisco
    Registry record
    NCT04267848 · updated
  2. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UCSF Medical Center-Mission Bay
    Registry record
    NCT04665739 · updated
  3. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Kaiser Permanente-San Francisco
    Registry record
    NCT06498635 · updated
  4. A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    UCSF Helen Diller Medical Center at Parnassus Heights - Neurology
    Registry record
    NCT06914128 · updated
  5. Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    UCSF- San Francisco (Helen Diller Family Comprehensive Cancer Center)
    Registry record
    NCT07080242 · updated
  6. A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    San Francisco Oncology Associates ( Site 0066)
    Registry record
    NCT06312137 · updated
  7. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    UCSF Medical Center at Mission Bay ( Site 0178)
    Registry record
    NCT06623422 · updated
  8. A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    UCSF Health - UCSF Helen Diller Family Comprehensive Cancer Center
    Registry record
    NCT07566052 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.

Prostate cancer studies recruiting in San Francisco

  1. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Amgen
    Study site
    University of California San Francisco
    Registry record
    NCT04221542 · updated
  2. Sacral Neuromodulation for Male Overactive Bladder (MOAB)

    • No phase
    • Ages 18 and older
    • Male participants
    Sponsor
    Axonics, Inc.
    Study site
    University of California San Francisco
    Registry record
    NCT06511141 · updated
  3. 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    University of California, San Francisco
    Study site
    University of California, San Francisco
    Registry record
    NCT07145177 · updated
  4. A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    Hoffmann-La Roche
    Registry record
    NCT07287150 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.

Melanoma studies recruiting in San Francisco

  1. A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Outpace Bio, Inc.
    Study site
    UCSF - Helen Diller Family Comprehensive Cancer Center
    Registry record
    NCT07664735 · updated
  2. Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    University of California, San Francisco
    Study site
    University of California, San Francisco
    Registry record
    NCT07148245 · updated
  3. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    University of California San Francisco (UCSF)
    Registry record
    NCT06246916 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in San Francisco, CA on ClinicalTrials.gov.

Lymphoma studies recruiting in San Francisco

  1. Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Zuckerberg San Francisco General Hospital
    Registry record
    NCT06806033 · updated
  2. A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    University of California, San Francisco
    Registry record
    NCT07221500 · updated
  3. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Pacific Hematology Oncology Associates ( Site 0131)
    Registry record
    NCT06717347 · updated
  4. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UCSF Medical Center-Mission Bay
    Registry record
    NCT04546399 · updated
  5. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Kaiser Permanente-San Francisco
    Registry record
    NCT05675410 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in San Francisco, CA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in San Francisco

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    Investigative Site US034
    Registry record
    NCT07522073 · updated
  2. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    California Pacific Medical Center-Pacific Campus
    Registry record
    NCT04858334 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in San Francisco, CA on ClinicalTrials.gov.

Ask about studies near San Francisco

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in California

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call